IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Lee, et al.

Serial No.: 10/687,164

Filed: October 16, 2003

Title: AMIDES THAT INHIBIT

VANILLOID RECEPTOR SUBTYPE 1

(VR1) RECEPTOR

Case No.: 7031US01

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450 on:

Date of Deposit: February 9, 2004

Tanua Delant

Date

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

Respectfully submitted,

Lee, et al.

ABBOTT LABORATORIES Customer Number 23492

Telephone: (847) 935-7956 Facsimile: (847) 938-2623

Johanna M. Corbin

Registration No. 51,582

Attorney for Applicants




DATE: February 9, 2004 SHEET _1_ of _1_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE					ATTY. DOCKET NO.			SERIAL NO.			
(Modified) TATENTAND TRADEMARK OFFICE					7031US01			10/687,164			
INFORMATION DISCLOSURE					APPLICANT(S)						
STATEMENT BY APPLICANT					Lee, et al.						
					FILING DATE			GROUP			
(Use several sheets if necessary)					October 16, 2003			Not yet assigned			
(37 CFR 1.98 (b))											
U.S.PATENT DOCUMENTS EXAMINER SUB FILING											
EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	IN	VENTOR	CLASS		ASS			
	-									—	
	<u> </u>		<u></u>			I					
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION											
-		DOCUMENT NUMBER	PUBLIC-ATION DATE		OUNTRY OR TENT OFFIC			SUB CLASS	TRANS- LATION		
		NOMBER							YES NO		
				Ì							
OTHER DOCUMENTS (* 1)											
OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication) Cl Abromovitch et al., "Arylpyridines, Part I. Orientation in the reaction of											
X		phenyllithium with	some 3-subst	substituted pyridines," Can. J. Chem. 38:761-771							
		(1960)									
+	C2	Caterina et al., "Impaired nociception and pain sensation in mice lacking the capsaicin receptor," Science 288:306-313 (2000)									
	C3	Caterina et al., "The capsaicin receptor: a heat-activated ion channel in the pain									
<i>P</i>		pathway," Nature 289:816-824 (1997)									
X.	C4	Caterina et al., "The vanilloid receptor: a molecular gateway to the pain pathway," Annu. Rev. Neurosci. 24:487-517 (2001)									
	C5	Collier et al., "The abdominal constriction response and its suppression by									
<u> </u>		analgesic drugs in the mouse," Br. J. Pharmac. Chemother. 32:295-310 (1968)									
P	C6	Davis et al., "Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia," Nature 405:183-187 (2000)									
	C7	Fowler, "Intravesical treatment of overactive bladder," Urology 55(Supp. 5A):60-									
<u> </u>		64 (2000)									
Į.	C8	Hayes et al., "Cloning and functional expression of a human orthologue of rat vanilloid receptor-1," Pain 88:205-215 (2000)									
	C9	Jones, "The synthesis of some amines and amino acids containing the pyrazole									
9		nucleus," J. Am. Chem. Soc. 71:3994-4000 (1949)									
P	C10	Loew, Chem. Ber. 23:1452 (1890)									
- <u> </u>	CH	Nolano et al., "Topical capsaicin in humans: parallel loss of epidermal nerve fibers									
EXAMINER	A and pain sensation," Pain 81:135-145 (1999) EXAMINER DATE CONSIDERED										
DATE CONSIDERED											
FXAMINER: Initial citation considered. Draw line through citation if not in conformance and											

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)



IN THE UNITED STATES PATENT AND TRADMARK OFFICE

Serial No.: 10/687,164

Filed: October 16, 2003

Title: AMIDES THAT INHIBIT

VANILLOID RECEPTOR SUBTYPE 1

(VR1) RECEPTOR

Case No.: 7031US01

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450 on:

Date of Deposit: February 9, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Dear Sir:

Enclosed herewith for the patent application identified above entitled AMIDES THAT INHIBIT VANILLOID RECEPTOR SUBTYPE 1 (VR1) RECEPTOR are the following:

- 1. Information Disclosure Statement;
- 2. Form PTO 1449, in duplicate;
- 3. References as cited on PTO 1449 (11 references); and
- 4. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any additional Filing Fees required under 37 CFR §1.16, as well as any patent application processing fees under 37 CFR §1.17 associated with this communication for which full payment had not been tendered, to Deposit Account No. 01-0025.

Respectfully submitted,

Lee, et al.

ABBOTT LABORATORIES

Customer Number 23492 Telephone: (847) 935-7956

Facsimile: (847) 938-2623

Johanna M. Corbin

Registration No. 51,582

Attorney for Applicants